COVID-19 study on BDC (1,217 participants)

phs003063 — COVID-19: Post-Hospital Thromboprophylaxis A Multicenter, Adaptive,    Prospective, Randomized Trial Evaluating the Efficacy and Safety of    Antithrombotic Strategies in Patients with COVID-19 Following Hospital    Discharge (ACTIV-4C)

<p>This study is an adaptive, prospective, randomized trial designed to compare the effectiveness and safety of antithrombotic therapy with no antithrombotic therapy after hospitalization for 48 hours or longer for COVID-19. For Stage 1 of this study, participants will be randomized to either prophylactic anticoagulation or no anticoagulant therapy for 30 days, and then followed for an additional 60 days after the completion of treatment (total duration of follow-up, approximately 90 days). Biobanking of samples for future biomarker and mechanistic studies will be available for centers able to participate and collect samples from eligible participants. Samples will be collected at the time of enrollment and after the completion of 30 days of therapy.</p>

COVID-19: Post-Hospital Thromboprophylaxis A Multicenter, Adaptive,    Prospective, Randomized Trial Evaluating the Efficacy and Safety of    Antithrombotic Strategies in Patients with COVID-19 Following Hospital    Discharge (ACTIV-4C)